Veradermics, Incorporated
NYSE:MANE · New York Stock Exchange
-$1.13 today
Vol 0.82M · Avg 0.58M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 3 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$70.0M -164.3% | -$26.5M -60.6% | -$16.5M | $510.0M | $498.8M | $487.6M |
| Depreciation & Amortization | $0 | $0 | $0 | $419.0M | $1.2B | $374.2M |
| Deferred Income Tax | $0 | $0 | $0 | $1.0B | $1.2B | $1.4B |
| Stock-Based Compensation | $1.4M | $0 -100.0% | $206.0K | $1.1B | $623.4M | $489.0M |
| Change in Working Capital | -$3.9M -630.9% | $732.0K -20.4% | $920.0K | $921.6M | $484.8M | $350.4M |
| Accounts Receivables | $0 | $0 | $0 | $559.0M | $1.3B | $592.6M |
| Inventory | $0 | $0 | $0 | $686.4M | $854.4M | $1.0B |
| Accounts Payables | -$122.0K -118.9% | $646.0K -52.3% | $1.4M | $1.5B | $657.0M | $948.2M |
| Other Working Capital | -$3.8M -4476.7% | $86.0K +119.8% | -$434.0K | $533.8M | $1.3B | $567.4M |
| Other Non-Cash Items | $839.0K -59.4% | $2.1M +11.5% | $1.9M | $1.3B | $1.2B | $1.4B |
| Operating Cash Flow | -$71.6M -202.3% | -$23.7M -75.3% | -$13.5M | $3.8B | $5.5B | $7.2B |
| Capital Expenditures | -$24.0K | $0 | $0 | $328.0M | $1.0B | $664.0M |
| Acquisitions (Net) | $0 | $0 | $0 | $903.4M | $769.0M | $937.0M |
| Purchases of Investments | -$143.9M | $0 | $0 | $713.0M | $578.6M | $444.2M |
| Sales of Investments | $25.0M | $0 | $0 | -$1.5B | $1.0B | $822.2M |
| Other Investing Activities | $0 | $0 | $0 | $1.4B | $862.8M | $616.4M |
| Investing Cash Flow | -$118.9M | $0 | $0 | -$15.4B | $3.1B | $4.8B |
| Debt Repayment | $0 -100.0% | $7.7M | $0 | -$1.6B | $602.4M | $680.8M |
| Common Stock Issued | $156.0K -99.7% | $52.8M | $0 | $442.8M | $610.8M | $778.8M |
| Common Stock Repurchased | $0 | $0 | $0 | $923.0M | $486.2M | $351.8M |
| Dividends Paid | $0 | $0 | $0 | $1.5B | -$1.6B | $535.2M |
| Other Financing Activities | -$447.0K | $0 +100.0% | -$35.0K | $966.4M | $720.0M | -$1.6B |
| Financing Cash Flow | $159.1M +163.1% | $60.5M +335.2% | $13.9M | $11.8B | $10.5B | $12.2B |
| Effect of Forex Changes | $0 | $0 | $0 | -$1.5B | $1.4B | $1.3B |
| Net Change in Cash | -$31.3M -185.1% | $36.8M +9455.3% | $385.0K | -$16.8B | -$15.5B | $3.2B |
| Free Cash Flow | -$71.6M -202.4% | -$23.7M -75.3% | -$13.5M | $9.0B | $14.3B | $8.6B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.05B
Abeona Therapeutics Inc.
NASDAQ:ABEO
$324.30M
Ovid Therapeutics Inc.
NASDAQ:OVID
$309.27M
Cybin Inc. Common Stock
NASDAQ:HELP
$225.02M
Tharimmune, Inc.
THAR
$139.94M
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
$110.57M
Lisata Therapeutics, Inc.
LSTA
$32.56M
XTL Biopharmaceuticals Ltd.
XTLB
$5.69M
Adial Pharmaceuticals, Inc.
ADIL
$2.68M
Dermata Therapeutics, Inc.
DRMA
$863,260.00
SEC Filings
Recent regulatory filings
No filings found.
Does MANE generate free cash flow?
Veradermics, Incorporated (MANE) generated -$71,626,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does MANE produce?
Operating cash flow was -$71,602,000.00, before capital expenditures of $24,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.